Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | M6PR | P20645 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 2/20 | 0.31 |
| ▸ | SELL | P14151 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
| ▸ | IDUA | P35475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19774832 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL18271877 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL26715975 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL11915786 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL16392508 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL26715981 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL17636458 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL18269757 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL19488918 | 0.89 | F10 (0.39) | M6PR | |
| SCHEMBL18969723 | 0.89 | F10 (0.39) | M6PR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697693-B2 | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697693-B2 | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto | NOS1, NOS2, NOS3 | SUCNR1 386/4885CA9 2952/4885CA12 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.